Replimune (REPL) Profit After Tax (2017 - 2025)
Replimune's (REPL) quarterly Profit After Tax came in at -$70.9 million in Q4 2025, down 6.94% year-on-year from -$76.2 million in Q4 2024, and up 14.68% quarter-over-quarter from -$83.1 million in Q3 2025.
Replimune (REPL) Profit After Tax (2017 - 2025) Analysis & Trends
Replimune has disclosed Profit After Tax across 9 years of filings, most recently posting -$70.9 million for Q4 2025.
- Profit After Tax for Q4 2025 came in at -$70.9 million, down 6.94% year-over-year; the trailing twelve-month figure through Dec 2025 was -$314.8 million (down 38.18% YoY), and the FY2025 annual result was -$247.3 million, down 14.82% from the prior year.
- Profit After Tax came in at -$70.9 million for Q4 2025 at Replimune, up from -$83.1 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$21.5 million in Q1 2021 to a low of -$86.7 million in Q2 2025.
- The 5-year median for Profit After Tax is -$50.3 million (2023), against an average of -$50.8 million.
- Across the five-year window, Profit After Tax advanced 11.64% in 2024 and tumbled 61.22% in 2025, its largest moves.
- Replimune's Profit After Tax stood at -$29.7 million in 2021, then plunged by 33.75% to -$39.7 million in 2022, then dropped by 28.8% to -$51.1 million in 2023, then declined by 29.69% to -$66.3 million in 2024, then slipped by 6.94% to -$70.9 million in 2025.
- The last three Profit After Tax figures came in at -$70.9 million (Q4 2025), -$83.1 million (Q3 2025), and -$86.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.74 Mn |
| 10 | Replimune | 780.01 Mn | 510.88 Mn | - | -70.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -70.90 Mn |
| Sep 30, 2025 | -83.10 Mn |
| Jun 30, 2025 | -86.69 Mn |
| Mar 31, 2025 | -74.10 Mn |
| Dec 31, 2024 | -66.30 Mn |
| Sep 30, 2024 | -53.06 Mn |
| Jun 30, 2024 | -53.77 Mn |
| Mar 31, 2024 | -54.69 Mn |
| Dec 31, 2023 | -51.12 Mn |
| Sep 30, 2023 | -60.04 Mn |
| Jun 30, 2023 | -49.56 Mn |
| Mar 31, 2023 | -49.00 Mn |
| Dec 31, 2022 | -39.69 Mn |
| Sep 30, 2022 | -43.10 Mn |
| Jun 30, 2022 | -42.25 Mn |
| Mar 31, 2022 | -31.70 Mn |
| Dec 31, 2021 | -29.67 Mn |
| Sep 30, 2021 | -29.36 Mn |
| Jun 30, 2021 | -27.31 Mn |
| Mar 31, 2021 | -21.50 Mn |